Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Retrospective analysis of clinical characteristics and outcomes for anal cancer patients in the South West Sydney Local Health District (SWSLHD) between 2010-2017 (#171)

Andrew O Parsonson 1 , Mark Lee 1 , Karen Wong 1 , Ray Asghari 2 , Christopher Henderson 3 , Annette Tognela 4 , Aflah Roohullah 4 , Kate Wilkinson 1 , Stephanie Lim 4 , Pei N Ding 1 , Michael Lin 5 , Weng L Ng 1 , Wei Chua 1
  1. Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW, Australia
  2. Bankstown Cancer Therapy Centre, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia
  3. Department of Anatomical Pathology, Liverpool Hospital, Sydney, NSW, Australia
  4. Macarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, NSW, Australia
  5. Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, New South Wales, Australia

We aim to examine the clinicopathological characteristics, diagnostic and treatment patterns and outcomes of patients diagnosed with anal cancer in SWSLHD between 2010 and 2017.

Retrospective review of patients diagnosed with anal cancer identified from the institutional oncology electronic database. Patient and tumour characteristics, demographics, diagnostic imaging, treatment and survival data were collected.

Sixty-eight patients were identified over the study period. The median age was 61 years, 29% male and 88% ECOG 0-1. Most patients (90%) had stage 1-3 disease at diagnosis with predominant histology of squamous cell carcinoma (90%). p16 immunohistochemistry was reported in a minority of cases (34%). 90% of patients had initial staging with CT and/or PET scan (65%) with 85% of patients having a post-treatment CT scan and/or PET scan (38%). 82% of patients received primary chemoradiotherapy, most commonly with mitomycin/5-flurouracil (66%) and 91% of patients completed planned treatment. 16% of treatment related adverse events were Grade 3 or higher and there were no treatment-related deaths. 72% of patients with stage 1-3 disease had a complete response and 28% partial response at post-treatment review. 24% of patients had progressive disease of which 75% developed metastatic disease and 25% recurred locally. 38% of patients who had progressive disease underwent second-line chemotherapy and 66% of patients who had incomplete response or local progression had salvage surgery. 22% of patients were deceased at time of data collection.

The majority of patients diagnosed with anal cancer received concurrent chemoradiotherapy with curative intent with high response rate and good tolerance. These results will be explored including correlation of outcomes with diagnostic, laboratory and histopathology variables to determine prognostic markers and guide prospective research.